Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Madrigal Pharmaceuticals (NASDAQ:MDGL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)